Breast cancer is a challenge best faced together Axillary management after neoadjuvant treatment

Neoadjuvant systemic therapy (NAST) facts



Why is NAST beneficial for breast cancer patients?

Aim: de-escalation of cancer treatment

- ✓ Shrink or eradicate the tumour in the breast and lymph nodes
- Monitor systemic therapy response and its modification, if required
- Enable less radical cancer surgery in breast and axilla (BCS and TAD)
- ✓ Fewer co-morbidities and better cosmetic outcome lead to improved quality of life for patients

Sysmex solution for TAD

MAGSEED® PLACEMENT

Benefits of Magseed[®] for marking target lymph nodes

- Simple and easy to place
- Designed with the patient in mind no radioactivity, reduced stress, less pain
- Smallest non-radioactive seed ideal for lymph node placement
- ✓ Spiral shape optimises tissue in-growth and visibility under imaging

IMPLANTATION TIME DURING NAST

Perfect orientation from placement to detection

- Can be implanted for as long as needed always realiably detectable by Sentimag[®]
- ✓ Surgical steel marker, very low nickel content
- ✓ Firmly implanted, no migration from soft tissue
- ✓ The patient won't feel it
- ✓ Visible under US and X-ray
- Vorisk of deactivation



www.sysmex-europe.com/breast-cancer



How does TAD improve axillary staging post-NAST?



Improving the accuracy, reducing the false negative rate (FNR)

> 10 % FNR if only sentinel lymph node biopsy (SLNB) is performed¹

< 2% FNR *if targeted axillary dissection* (TAD) is performed²



Tracer guided SLNB is combined with the removal of a previously positive and marked lymph node (target lymph node)

SURGERY

Sentimag[®]-Magseed[®]/Magtrace[®] – the world's only system for wire-free, non-radioactive TAD³

Both the Magseed[®] and Magtrace[®] are precisely located intraoperatively by the Sentimag[®] probe.



DIAGNOSIS

Accurate molecular sentinel lymph node assessment with OSNA

- ✓ Standardised and accurate results thanks to whole node analysis
- Highly sensitive amplification technology and quantification of metastatic burden
- ✓ No risk to overlook low volume residual disease
- ✓ 16 minutes to get a fully informed result
- Reliable intraoperative decision-making
- ✓ No risk of second surgeries due to false negative intraoperative results



Abbreviations

NAST: neoadjuvant systemic therapy BCS: breast conserving surgery SLNB: sentinel lymph node biopsy

TAD: targeted axillary dissection ALND: axillary lymph node dissection FNR: false negative rate

Prospective multicentre trials: ACOSOG Z1071, SENTINA, SN FNAC

² Caudle (2016) ³ 3 publications and 8 abstracts so far on LN localisation with Magseeds[®]; 270+ patients reported.

Non-inferior to gold standard in clinical trials involving 1,200+ patients - publication spotlight reference